logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Invasive Aspergillus Infections

    Medications for Invasive Aspergillus Infections

    FiltersReset Filters
    3 results

    • posaconazole

      (posaconazole)
      Par Pharmaceutical Inc.
      Usage: Posaconazole is indicated for treating invasive aspergillosis in patients aged 13 and older, prophylaxis of invasive Aspergillus and Candida infections in high-risk patients, and treating oropharyngeal candidiasis, including cases resistant to itraconazole or fluconazole, in patients aged 13 and older.

    • posaconazole

      (posaconazole)
      SpecGx LLC
      Usage: Posaconazole delayed-release tablets are indicated for the prophylaxis of invasive Aspergillus and Candida infections in severely immunocompromised patients, including those with hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease or prolonged neutropenia from chemotherapy, in adults and pediatric patients aged 13 and older.

    • posaconazole

      (POSACONAZOLE)
      Lupin Pharmaceuticals, Inc.
      Usage: Posaconazole delayed-release tablets are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients at high risk, including severe immunocompromised individuals, such as HSCT recipients with graft-versus-host disease or those with hematologic malignancies undergoing prolonged chemotherapy-induced neutropenia.